long-term visual outcome in wet age-related macular degeneration patients depending on the number of ranibizumab injections
Clicks: 160
ID: 245862
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
160 views
22 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #118 of 167 articles by views in chemical reviews
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 167 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Purpose. To analyse the visual outcome in wet age-related macular degeneration (AMD) patients depending on the number of ranibizumab injections. Methods. 51 naïve wet AMD patients were retrospectively recorded. Visual acuity (VA), central retinal thickness (CRT) measured with spectral domain (SD) optical coherence tomography (OCT), and number of intravitreal injections were compared at 6, 12, 18, 24, 30, and 36 months of follow-up. Kaplan-Meier survival rates (SRs) based on VA outcomes were calculated depending on the number of ranibizumab injections performed. Results. VA improved compared with baseline at 6 and 12 months (P<0.005). No differences were found at 18, 24, 30, and 36 months (P>0.05). CRT measured with Cirrus OCT decreased (P<0.001) at all time points analysed. The mean number of injections received was 6.98±3.69. At 36 months, Kaplan-Meier SR was 76.5% (the proportion of patients without a decrease in vision of more than 0.3 logMAR units). VA remained stable (≤0.01 logMAR units) or improved in 62.7%. Within this group, SR was 92.9% in those who received 7 or more injections versus 51.4% receiving <7 treatments (P=0.008; log-rank test). Conclusion. Better VA outcomes were found in stable wet AMD patients after 3 years of follow-up if they received ≥7 ranibizumab injections.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (92 words).
Try re-searching for a better abstract.
| Reference Key |
calvo2015journallong-term
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Pilar Calvo;Beatriz Abadia;Antonio Ferreras;Oscar Ruiz-Moreno;Jesús Leciñena;Clemencia Torrón |
| Journal | chemical reviews |
| Year | 2015 |
| DOI |
10.1155/2015/820605
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.